[
    [
        {
            "time": "2023-02-01",
            "original_text": "明日最具爆发力六大牛股（2月1日）",
            "features": {
                "keywords": [
                    "牛股",
                    "爆发力"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "明日最具爆发力六大牛股（2月1日）",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-02-01",
            "original_text": "医疗保健：从PE到DCF",
            "features": {
                "keywords": [
                    "医疗保健",
                    "PE",
                    "DCF"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗保健"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医疗保健：从PE到DCF",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-02-01",
            "original_text": "贝达药业：利润受研发支出等因素制约",
            "features": {
                "keywords": [
                    "贝达药业",
                    "利润",
                    "研发支出"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "贝达药业：利润受研发支出等因素制约",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-02-01",
            "original_text": "99股获券商买入评级，酒鬼酒目标涨幅达87.14%",
            "features": {
                "keywords": [
                    "券商",
                    "买入评级",
                    "酒鬼酒",
                    "目标涨幅"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "白酒"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "99股获券商买入评级，酒鬼酒目标涨幅达87.14%",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-02-01",
            "original_text": "[增持评级] 贝达药业(300558)业绩预告点评：业绩符合预期 埃克替尼销量大幅增长",
            "features": {
                "keywords": [
                    "贝达药业",
                    "业绩预告",
                    "埃克替尼",
                    "销量增长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[增持评级] 贝达药业(300558)业绩预告点评：业绩符合预期 埃克替尼销量大幅增长",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]